PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

Core Viewpoint - PharmAla Biotech Holdings Inc. has entered into a binding supply agreement with Amsterdam University Medical Center for the provision of LaNeo™ 40mg MDMA capsules for a proposed clinical trial [1][4]. Group 1: Agreement Details - The agreement stipulates that PharmAla will supply LaNeo™ 40mg capsules in a new single-capsule packaging format [2]. - A three-year stability testing program is included in the agreement, aimed at generating new stability data for the single-capsule dosage form [2][3]. - The stability data is essential for developing commercial-grade blister packaging, which is the standard for pharmaceutical distribution [3]. Group 2: Strategic Importance - The stability testing program will support PharmAla's broader commercial strategy by enabling more efficient distribution to clinical trial sites and commercial partners globally [3]. - The agreement expands PharmAla's European clinical footprint and is contingent upon executing a Quality Agreement with the Clinical Pharmacy of Amsterdam UMC [4]. - PharmAla aims to leverage the stability data for future commercial-grade packaging of LaNeo™ MDMA, marking a significant step towards a commercial-grade product [4]. Group 3: Company Background - PharmAla Biotech Holdings Inc. focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and is the only company provisioning clinical-grade MDMA for patient treatments outside of clinical trials [6]. - The company was founded to alleviate the backlog of generic, clinical-grade MDMA and to develop novel drugs in the same class [6]. - PharmAla's research and development unit has completed proof-of-concept research into several intellectual property families, including its lead drug candidate ALA-002 [6].